HUE061479T2 - Termelõ sejtvonal erõsítõk - Google Patents

Termelõ sejtvonal erõsítõk

Info

Publication number
HUE061479T2
HUE061479T2 HUE13729169A HUE13729169A HUE061479T2 HU E061479 T2 HUE061479 T2 HU E061479T2 HU E13729169 A HUE13729169 A HU E13729169A HU E13729169 A HUE13729169 A HU E13729169A HU E061479 T2 HUE061479 T2 HU E061479T2
Authority
HU
Hungary
Prior art keywords
cell line
production cell
line enhancers
enhancers
production
Prior art date
Application number
HUE13729169A
Other languages
English (en)
Inventor
Gang Chen
Darya Burakov
Dipali Deshpande
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HUE061479T2 publication Critical patent/HUE061479T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
HUE13729169A 2012-05-29 2013-05-29 Termelõ sejtvonal erõsítõk HUE061479T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261652549P 2012-05-29 2012-05-29

Publications (1)

Publication Number Publication Date
HUE061479T2 true HUE061479T2 (hu) 2023-07-28

Family

ID=49670701

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13729169A HUE061479T2 (hu) 2012-05-29 2013-05-29 Termelõ sejtvonal erõsítõk

Country Status (21)

Country Link
US (9) US9079954B2 (hu)
EP (3) EP3564262A1 (hu)
JP (5) JP6298455B2 (hu)
KR (3) KR102126210B1 (hu)
CN (2) CN110835624A (hu)
AU (4) AU2013267525B2 (hu)
BR (1) BR112014029095A2 (hu)
CA (1) CA2873131A1 (hu)
DK (1) DK2875047T3 (hu)
EA (2) EA201792213A1 (hu)
ES (1) ES2940900T3 (hu)
FI (1) FI2875047T3 (hu)
HK (1) HK1205137A1 (hu)
HU (1) HUE061479T2 (hu)
IL (3) IL235573B (hu)
MX (1) MX360359B (hu)
PL (1) PL2875047T3 (hu)
SG (2) SG10201606654XA (hu)
TW (2) TWI641687B (hu)
WO (1) WO2013181253A1 (hu)
ZA (1) ZA201408289B (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
BR112018071283A2 (pt) 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
KR20180134894A (ko) 2016-04-20 2018-12-19 리제너론 파마슈티칼스 인코포레이티드 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
WO2018081448A1 (en) 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
CN116327963A (zh) 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
CA3067735A1 (en) 2017-08-17 2019-02-21 Just Biotherapeutics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60211329T2 (de) 2001-01-16 2007-05-24 Regeneron Pharmaceuticals, Inc. Isolierung von sezernierte proteine exprimierenden zellen
CA2485939C (en) 2002-05-29 2013-10-29 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
EP1572944A4 (en) 2002-08-30 2007-12-26 Harvard College METHOD AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF XBP-1
AU2004248165A1 (en) 2003-06-11 2004-12-23 Biogen Idec Ma Inc. Method to increase protein production in culture
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
JP2007537728A (ja) * 2004-03-31 2007-12-27 セントカー・インコーポレーテツド タンパク質生産速度の変更方法
DK1781698T3 (en) 2004-07-20 2016-10-03 Genentech Inc COMPOSITIONS AND METHODS FOR THE USE OF Angiopoietin-like-4-PROTEIN
ES2653843T3 (es) * 2004-09-02 2018-02-09 Wyeth Llc Sistemas y procedimientos de producción de proteínas
AU2005284798B2 (en) * 2004-09-15 2012-02-02 The President And Fellows Of Harvard College Reducing ER stress in the treatment of obesity and diabetes
EP1964922A1 (en) * 2007-03-02 2008-09-03 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
EP2129685B1 (en) 2007-03-21 2013-11-20 Danisco US Inc. Over expression of foldases and chaperones improves protein production
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2009020802A2 (en) * 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EP2209891A1 (en) 2007-11-13 2010-07-28 Boehringer Ingelheim Pharma GmbH & Co. KG Improving the secretory capacity in host cells
US20090247609A1 (en) * 2007-12-20 2009-10-01 Hitto Kaufmann Sm-protein based secretion engineering
CA2726289A1 (en) 2008-05-28 2009-12-23 Bayer Healthcare Llc Methods and compositions for production of recombinant protein in hbx-expressing mammalian cells
US20110142799A1 (en) 2008-06-23 2011-06-16 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
GB0902180D0 (en) 2009-02-10 2009-03-25 Ucb Pharma Sa Method for producing protein
US8722046B2 (en) * 2009-04-08 2014-05-13 The United States Of America As Represented By The Secretary Of The Army Human monoclonal antibodies protective against bubonic plague
KR101441437B1 (ko) 2009-06-02 2014-09-25 리제너론 파마슈티칼스 인코포레이티드 푸코실화-결핍 세포
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JO3274B1 (ar) * 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法

Also Published As

Publication number Publication date
US20190270800A1 (en) 2019-09-05
TW201823460A (zh) 2018-07-01
ZA201408289B (en) 2016-09-28
DK2875047T3 (da) 2023-03-27
USRE48651E1 (en) 2021-07-20
WO2013181253A1 (en) 2013-12-05
BR112014029095A2 (pt) 2017-07-18
US9228012B2 (en) 2016-01-05
US20150353634A1 (en) 2015-12-10
US9688751B2 (en) 2017-06-27
EA201792213A1 (ru) 2018-01-31
US10227401B2 (en) 2019-03-12
EA201492242A1 (ru) 2015-05-29
SG11201407652RA (en) 2014-12-30
CA2873131A1 (en) 2013-12-05
AU2021240303A1 (en) 2021-10-28
EA028790B1 (ru) 2017-12-29
JP2022044609A (ja) 2022-03-17
JP7382383B2 (ja) 2023-11-16
KR102126210B1 (ko) 2020-06-25
US10351622B2 (en) 2019-07-16
KR102346867B1 (ko) 2022-01-04
KR20230065370A (ko) 2023-05-11
US20150175688A1 (en) 2015-06-25
MX2014014630A (es) 2015-02-12
US20170291938A1 (en) 2017-10-12
FI2875047T3 (fi) 2023-03-30
US20160304598A1 (en) 2016-10-20
SG10201606654XA (en) 2016-10-28
HK1205137A1 (en) 2015-12-11
AU2013267525A1 (en) 2014-12-11
IL265867A (en) 2019-06-30
CN110835624A (zh) 2020-02-25
CN104350068A (zh) 2015-02-11
JP2020022514A (ja) 2020-02-13
EP4219546A2 (en) 2023-08-02
JP6622334B2 (ja) 2019-12-18
EP3564262A1 (en) 2019-11-06
EP2875047B1 (en) 2023-01-25
US20150299309A1 (en) 2015-10-22
AU2018201094A1 (en) 2018-03-15
JP2018108094A (ja) 2018-07-12
MX360359B (es) 2018-10-30
US10611831B2 (en) 2020-04-07
PL2875047T3 (pl) 2023-05-29
TWI641687B (zh) 2018-11-21
AU2013267525B2 (en) 2017-11-16
IL235573B (en) 2019-09-26
TW201402815A (zh) 2014-01-16
JP2015518728A (ja) 2015-07-06
AU2019203780A1 (en) 2019-06-20
KR20150015492A (ko) 2015-02-10
US9382315B2 (en) 2016-07-05
ES2940900T3 (es) 2023-05-12
AU2019203780B2 (en) 2021-07-01
CN104350068B (zh) 2019-12-03
US20150299310A1 (en) 2015-10-22
EP4219546A3 (en) 2023-08-23
AU2018201094B2 (en) 2019-06-20
KR102528950B1 (ko) 2023-05-08
KR20220003165A (ko) 2022-01-07
JP2023153268A (ja) 2023-10-17
KR20200074273A (ko) 2020-06-24
US9193786B2 (en) 2015-11-24
IL235573A0 (en) 2015-01-29
EP2875047A1 (en) 2015-05-27
IL279922A (en) 2021-03-01
JP7037535B2 (ja) 2022-03-16
JP6298455B2 (ja) 2018-03-20
US20130323788A1 (en) 2013-12-05
US9079954B2 (en) 2015-07-14

Similar Documents

Publication Publication Date Title
HK1211623A1 (en) Cell lines
GB201301173D0 (en) Object production
EP2725091A4 (en) DEVICE FOR PRODUCING A CELL STRUCTURE
AU347859S (en) Battery
AU346864S (en) Battery
EP2824749A4 (en) BATTERY WITH A COATED STRUCTURE
EP2911230A4 (en) CELL
IL279922A (en) Amplifiers of production cell lines
EP2939306A4 (en) DRUMS
SG11201500417PA (en) Cell culture
EP2831949A4 (en) SODIUM OXYGEN CELLS
EP2898114A4 (en) HYDROGEN PRODUCTION
AU2013200983B9 (en) Hydrogen production
EP2830138A4 (en) BIO FUEL CELL
EP2922109A4 (en) SOLAR CELL
EP2939294A4 (en) DRUMS
EP2804221A4 (en) CIGS COMPOUND SOLAR BATTERY
EP2863459A4 (en) FLAT CELL
EP2874200A4 (en) FLAT BATTERY
SG11201405540QA (en) A cell arrangement
EP2919288A4 (en) SOLAR CELL
GB201211873D0 (en) Cell culture
EP2911227A4 (en) FLAT BATTERY
GB201218045D0 (en) Battery
EP2824177A4 (en) NEW CELLULASE